Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

New Culprit Identified in Metabolic Syndrome

August 8, 2014 3:11 pm | by Julia Evangelou Strait | News | Comments

A new study suggests uric acid - a normal waste product removed from the body by the kidneys and intestines and released in urine and stool - may play a role in causing metabolic syndrome, a cluster of risk factors that increases the risk of heart disease and type 2 diabetes. Read more...


Neurovance Completes Enrollment in Abuse Liability Study

August 8, 2014 3:05 pm | News | Comments

Neurovance Inc. announced that it has completed enrollment in a human abuse liability study of centanafadine (formerly EB-1020), a novel non-stimulant being developed for the treatment of adults with attention deficit hyperactivity disorder (ADHD). Read more...


Discovery IDs a New Class of Antibiotics

August 8, 2014 3:00 pm | News | Comments

St. Jude Children's Research Hospital scientists have discovered an enzyme -  fatty acid kinase - that regulates production of the toxins that contribute to potentially life-threatening Staphylococcus aureus infections. Read more...


WHO Declares Ebola Outbreak an International Public Health Emergency

August 8, 2014 2:47 pm | by Maria Cheng, AP Medical Writer | News | Comments

The World Health Organization urged nations worldwide Friday to donate money and resources to stop the spread of Ebola as it declared the outbreak in West Africa to be an international public health emergency, having so far killed at least 961 people. Read more...


Breaking News: China Jails British-US Investigator Couple

August 8, 2014 1:50 pm | News | Comments

A Briton and an American were sentenced to prison on Friday on charges of illegally trading in the personal details of Chinese citizens after they testified they bought such information to help companies combat fraud and acknowledged having obtained personal details about Chinese nationals. Read more...


3SBio, DiNonA Partner on Leukemia mAb

August 8, 2014 10:46 am | News | Comments

3SBio Inc. announced it has entered into an exclusive license with DiNonA Inc. for the development, manufacturing and marketing of Leukotuximab, an anti JL-1 antibody for acute leukemia, including acute myelocytic leukemia and acute lymphoblastic leukemia, in the territory of Greater China and the Middle East. Read more...


EMA Accepts Application for New Pneumococcal Vaccine Indication

August 8, 2014 10:41 am | News | Comments

Pfizer Inc. announced that the European Medicines Agency has accepted Pfizer’s application seeking to expand the indication for Prevenar 13 in adults to include the prevention of pneumonia caused by the 13 pneumococcal serotypes contained in the vaccine. Read more...


Charity, Industry Join Forces on Pancreatic Cancer Drugs

August 8, 2014 10:35 am | News | Comments

Cancer Research UK and its commercial arm, Cancer Research Technology, are to join forces with Astellas Pharma Inc. to find new drug targets in the fight against cancer, with an initial focus on pancreatic cancer, one of the deadliest forms of cancer. Read more...


British, US Couple Testify in Chinese Trial

August 8, 2014 10:28 am | News | Comments

A Briton and an American charged with illegally trading in the personal details of Chinese nationals testified Friday that they bought such information to help companies combat fraud under contract for British pharmaceutical giant GlaxoSmithKline, which is accused in a separate case of bribing Chinese doctors and hospitals to use its products. Read more...


Splicing Modifiers May Correct Spinal Muscular Atrophy Deficit

August 8, 2014 10:03 am | News | Comments

The journal Science published results of a preclinical study demonstrating that treatment with orally available RNA splicing modifiers of the SMN2 gene starting early after birth is preventing deficits in mouse models of Spinal Muscular Atrophy. Read more...


FDA Lifts Hold on Tekmira’s Experimental Ebola Drug

August 8, 2014 9:55 am | by Matthew Perrone, AP Health Writer | News | Comments

U.S. health authorities have eased safety restrictions on an experimental drug to treat Ebola, a move that could clear the way for its use in patients infected with the deadly virus, prompting praise by Tekmira's CEO Mark Murray on Thursday. Read more...


Breath Reveals Hidden Image in Anti-Counterfeit Labels

August 7, 2014 1:00 pm | Videos | Comments

Counterfeit drugs, which at best contain wrong doses and at worst are toxic, are thought to kill more than 700,000 people per year. To fight back against counterfeiting, researchers have developed a way to make labels that change when you breathe on them, revealing a hidden image. Read more...


Cure to Lung Cancer May Depend on Your DNA

August 7, 2014 1:00 pm | News | Comments

The Northside Hospital Cancer Institute announced its participation in a unique National Cancer Institute clinical collaboration to treat lung cancer based on a person’s genetic makeup. Read more...               


FDA Approves Orbactiv to Treat Skin Infections

August 7, 2014 1:00 pm | News | Comments

The FDA approved Orbactiv (oritavancin), a new antibacterial drug to treat adults with skin infections, including Staphylococcus aureus, various Streptococcus species and Enterococcus faecalis. Read more...         


Ethical Issue: Who Gets Experimental Ebola Drug?

August 7, 2014 1:00 pm | News | Comments

The use of an experimental drug to treat two Americans diagnosed with Ebola is raising ethical questions about who gets first access to unproven new therapies for the deadly disease. Read more...                



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.